Lisa M. C. van Hoogstraten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lisa M. C. van Hoogstraten has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Lambertus A. Kiemeney
Department of Urology Radboud University Medical Center Nijmegen The Netherlands
5 shared publications- Lambertus Alm Kiemeney
Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
5 shared publications Antoine G. van der Heijden
Radboud University Medical Center
4 shared publicationsJ. Alfred Witjes
Department of Urology Radboud University Medical Center Nijmegen The Netherlands
4 shared publications- Katja K. H. Aben
Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands
4 shared publications Richard P. Meijer
Department of Oncological Urology University Medical Center Utrecht Utrecht The Netherlands
4 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (4)
Impact of diagnostic transurethral bladder tumour resection on the release of circulating tumour cells
Objective: To evaluate the impact of transurethral resection of the bladder tumour (TURBT) on the release of circulating tumour cells (CTCs) in patients suspected of having muscle-invasive bladder cancer (MIBC) and to assess metastasis in follow-up analysis. Materials and methods: In this prospective pilot study for the BladParadigm trial, patients suspected of having MIBC were recruited and underwent TURBT for local staging. Peripheral blood samples were collected just before and immediately after TURBT. CTCs were enriched using the Parsortix® PR1 microfluidics system. Cytokeratin-positive CTCs were counted using fluorescence microscopy. Progression and survival were evaluated at 2 years since inclusion. Results: Of 18 patients included, seven were diagnosed with NMIBC and eleven with MIBC. Of all MIBC patients, 1 patient was already CTC-positive before TURBT. Four other MIBC patients were CTC-positive only after TURBT, indicating a CTC rise after TURBT in 40% (4/10) of pre-TURBT CTC-negative MIBC cases. Two out of these four patients experienced progression within two years, of whom one deceased. Two out of six CTC-negative patients before and after TURBT also experienced progression. Conclusion: We demonstrate the feasibility of using label-free enrichment to capture and enumerate bladder cancer-derived CTCs. Our findings indicate that TURBT might lead to the spread of CTCs. Although this feasibility study lacks power, the detection of TURBT-associated CTCs suggests a need to study non-invasive alternatives for local staging of bladder cancer.
- 15 October 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (4)
Open AccessImpact of diagnostic transurethral bladder tumour resection on the release of circulating tumour cells
Objective: To evaluate the impact of transurethral resection of the bladder tumour (TURBT) on the release of circulating tumour cells (CTCs) in patients suspected of having muscle-invasive bladder cancer (MIBC) and to assess metastasis in follow-up analysis. Materials and methods: In this prospective pilot study for the BladParadigm trial, patients suspected of having MIBC were recruited and underwent TURBT for local staging. Peripheral blood samples were collected just before and immediately after TURBT. CTCs were enriched using the Parsortix® PR1 microfluidics system. Cytokeratin-positive CTCs were counted using fluorescence microscopy. Progression and survival were evaluated at 2 years since inclusion. Results: Of 18 patients included, seven were diagnosed with NMIBC and eleven with MIBC. Of all MIBC patients, 1 patient was already CTC-positive before TURBT. Four other MIBC patients were CTC-positive only after TURBT, indicating a CTC rise after TURBT in 40% (4/10) of pre-TURBT CTC-negative MIBC cases. Two out of these four patients experienced progression within two years, of whom one deceased. Two out of six CTC-negative patients before and after TURBT also experienced progression. Conclusion: We demonstrate the feasibility of using label-free enrichment to capture and enumerate bladder cancer-derived CTCs. Our findings indicate that TURBT might lead to the spread of CTCs. Although this feasibility study lacks power, the detection of TURBT-associated CTCs suggests a need to study non-invasive alternatives for local staging of bladder cancer.
- Open Access
- 23 February 2026
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 16 (2-3) , 22-27
Sneller, veiliger, slimmer: mpMRI voor stadiëring van spierinvasieve blaaskanker?
Samenvatting: De prognose van patiënten met spierinvasieve blaaskanker (MIBC) is de afgelopen dertig jaar nauwelijks verbeterd. In Nederland wordt jaarlijks bij circa 2.200 patiënten MIBC vastgesteld. Ondanks een in opzet curatieve lokale behandeling overlijdt ongeveer de helft van deze patiënten binnen vijf jaar na de diagnose. Dit wijst erop dat de ziekte ten tijde van de initiële behandeling bij een deel van de patiënten reeds gemetastaseerd is. Een mogelijke verklaring is dat de huidige standaardmethode voor lokale stadiëring – het op de operatiekamer zo volledig mogelijk verwijderen van de tumor middels transurethrale resectie (TURT) – kan bijdragen aan tumorcelverspreiding. In Nederland loopt momenteel een gerandomiseerd, tweearmig onderzoek dat analyseert of een blaas-MRI in combinatie met een poliklinisch biopt een veiliger, kosteneffectiever en sneller alternatief vormt voor het aantonen van spierinvasie bij blaaskanker, dan de conventionele TURT. Daarnaast wordt onderzocht of deze aanpak de tijd tot definitieve behandeling kan verkorten. Indien succesvol, kan dit een belangrijke stap voorwaarts betekenen in de diagnostiek en behandeling van blaaskanker.
- 23 February 2026
- Published by Springer Nature in Tijdschrift voor Urologie
- Vol. 16 (2-3) , 22-27
Open AccessSneller, veiliger, slimmer: mpMRI voor stadiëring van spierinvasieve blaaskanker?
Samenvatting: De prognose van patiënten met spierinvasieve blaaskanker (MIBC) is de afgelopen dertig jaar nauwelijks verbeterd. In Nederland wordt jaarlijks bij circa 2.200 patiënten MIBC vastgesteld. Ondanks een in opzet curatieve lokale behandeling overlijdt ongeveer de helft van deze patiënten binnen vijf jaar na de diagnose. Dit wijst erop dat de ziekte ten tijde van de initiële behandeling bij een deel van de patiënten reeds gemetastaseerd is. Een mogelijke verklaring is dat de huidige standaardmethode voor lokale stadiëring – het op de operatiekamer zo volledig mogelijk verwijderen van de tumor middels transurethrale resectie (TURT) – kan bijdragen aan tumorcelverspreiding. In Nederland loopt momenteel een gerandomiseerd, tweearmig onderzoek dat analyseert of een blaas-MRI in combinatie met een poliklinisch biopt een veiliger, kosteneffectiever en sneller alternatief vormt voor het aantonen van spierinvasie bij blaaskanker, dan de conventionele TURT. Daarnaast wordt onderzocht of deze aanpak de tijd tot definitieve behandeling kan verkorten. Indien succesvol, kan dit een belangrijke stap voorwaarts betekenen in de diagnostiek en behandeling van blaaskanker.
- Open Access
Surveillance patterns in non-muscle invasive bladder cancer across risk groups: a real-world analysis
OBJECTIVE: To provide insight into real-world surveillance practices for patients with low risk (LR), intermediate risk (IR), and (very) high risk (HR) non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Cystoscopy surveillance patterns were analysed using real-world data from two population-based cohort studies in the Netherlands, comparing practices to guideline recommendations by risk group. As bladder cancer-related symptoms may prompt diagnostic investigations beyond routine follow-up, we evaluated the occurrence of such symptoms and the use of various diagnostics including cystoscopy in a subset of patients with available data. RESULTS: In total, 2,791 primary and recurrent tumours were included in the analyses. Among patients with LR NMIBC, 37.6% were monitored more intensively than recommended. The average number of cystoscopies in the first follow-up year was 1.3 (range 0-4). IR NMIBCs were generally monitored in accordance with guideline recommendations. However, adherence declined over the years following diagnosis, dropping from 78.1% to 59.3%. The proportion of IR NMIBCs who were monitored less than recommended increased from 21.7% to 39.8%. Most HR NMIBCs (88.2%) were monitored less than recommended, though adherence improved over time. In-depth analysis of 204 tumours revealed that next to cystoscopy, cytology was frequently employed, increasing with risk group (LR: 50.0%, IR: 52.3%, HR: 88.9%). Imaging (25%-65%) and biopsies (25%-85%) were also commonly performed. Surveillance patterns varied especially among IR NMIBCs. Symptoms were reported in approximately one third of bladder tumours during follow-up, but did not appear to affect surveillance patterns. CONCLUSION: Our findings demonstrate substantial deviations from recommended NMIBC surveillance practices. Cystoscopy was overused in a considerable proportion of LR NMIBC and underused in most HR cases. Surveillance of IR NMIBCs was particularly heterogenous with considerable variation in diagnostic investigations. These insights highlight opportunities to refine NMIBC surveillance schedules, aiming to improve patient outcomes and optimize allocation of healthcare resources.
Open AccessSurveillance patterns in non-muscle invasive bladder cancer across risk groups: a real-world analysis
OBJECTIVE: To provide insight into real-world surveillance practices for patients with low risk (LR), intermediate risk (IR), and (very) high risk (HR) non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Cystoscopy surveillance patterns were analysed using real-world data from two population-based cohort studies in the Netherlands, comparing practices to guideline recommendations by risk group. As bladder cancer-related symptoms may prompt diagnostic investigations beyond routine follow-up, we evaluated the occurrence of such symptoms and the use of various diagnostics including cystoscopy in a subset of patients with available data. RESULTS: In total, 2,791 primary and recurrent tumours were included in the analyses. Among patients with LR NMIBC, 37.6% were monitored more intensively than recommended. The average number of cystoscopies in the first follow-up year was 1.3 (range 0-4). IR NMIBCs were generally monitored in accordance with guideline recommendations. However, adherence declined over the years following diagnosis, dropping from 78.1% to 59.3%. The proportion of IR NMIBCs who were monitored less than recommended increased from 21.7% to 39.8%. Most HR NMIBCs (88.2%) were monitored less than recommended, though adherence improved over time. In-depth analysis of 204 tumours revealed that next to cystoscopy, cytology was frequently employed, increasing with risk group (LR: 50.0%, IR: 52.3%, HR: 88.9%). Imaging (25%-65%) and biopsies (25%-85%) were also commonly performed. Surveillance patterns varied especially among IR NMIBCs. Symptoms were reported in approximately one third of bladder tumours during follow-up, but did not appear to affect surveillance patterns. CONCLUSION: Our findings demonstrate substantial deviations from recommended NMIBC surveillance practices. Cystoscopy was overused in a considerable proportion of LR NMIBC and underused in most HR cases. Surveillance of IR NMIBCs was particularly heterogenous with considerable variation in diagnostic investigations. These insights highlight opportunities to refine NMIBC surveillance schedules, aiming to improve patient outcomes and optimize allocation of healthcare resources.
- Open Access
- 16 April 2025
- Published by Wiley in BJU International
- Vol. 136 (4) , 657-668
The impact of treatment for muscle‐invasive bladder cancer on health‐related quality of life
Objectives: To evaluate the impact of treatment for localised muscle‐invasive bladder cancer (MIBC) during the first 2 years after diagnosis. Patients and Methods: A prospective cohort study was conducted including patients diagnosed with non‐metastatic (cM0) MIBC between November 2017 and November 2019 in the Netherlands. Health‐related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30) as well as the MIBC‐specific QLQ‐BLM30 module. Questionnaires were administered at baseline (pre‐treatment) and at 6, 12 and 24 months after diagnosis. Patients were grouped by treatment: neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), upfront RC, chemoradiation, and radiotherapy. Linear mixed models were used to assess HRQoL changes over time per treatment group. Results: A total of 518 patients participated in quality of life measurements (46% response rate). After excluding 14 patients who did not complete the EORTC QLQ‐C30 and 114 for baseline completion after start of treatment, a total of 390 patients were included of whom 105 underwent NAC and RC, 148 underwent upfront RC, 58 underwent chemoradiation, and 79 underwent radiotherapy alone. Over time, clinically relevant improvements in emotional functioning and future perspective were observed across all treatment groups. However, a temporary worsening in physical functioning was observed at 6 months. Patients treated with RC (with or without NAC) experienced persistent deteriorations in body image and sexual functioning up to at least 2 years after diagnosis, although urostomy‐related outcomes improved. Patients undergoing chemoradiation showed improvements in urinary symptoms, while those receiving radiotherapy reported significant worsening of dyspnoea over time. Conclusion: In this largest population‐based study to date on HRQoL in MIBC, HRQoL largely recovered to baseline levels during the first 2 years after diagnosis. However, persistent deteriorations in physical and cognitive functioning, body image, and sexual function were observed, particularly in patients treated with RC (with or without NAC).
- 16 April 2025
- Published by Wiley in BJU International
- Vol. 136 (4) , 657-668
Open AccessThe impact of treatment for muscle‐invasive bladder cancer on health‐related quality of life
Objectives: To evaluate the impact of treatment for localised muscle‐invasive bladder cancer (MIBC) during the first 2 years after diagnosis. Patients and Methods: A prospective cohort study was conducted including patients diagnosed with non‐metastatic (cM0) MIBC between November 2017 and November 2019 in the Netherlands. Health‐related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30) as well as the MIBC‐specific QLQ‐BLM30 module. Questionnaires were administered at baseline (pre‐treatment) and at 6, 12 and 24 months after diagnosis. Patients were grouped by treatment: neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), upfront RC, chemoradiation, and radiotherapy. Linear mixed models were used to assess HRQoL changes over time per treatment group. Results: A total of 518 patients participated in quality of life measurements (46% response rate). After excluding 14 patients who did not complete the EORTC QLQ‐C30 and 114 for baseline completion after start of treatment, a total of 390 patients were included of whom 105 underwent NAC and RC, 148 underwent upfront RC, 58 underwent chemoradiation, and 79 underwent radiotherapy alone. Over time, clinically relevant improvements in emotional functioning and future perspective were observed across all treatment groups. However, a temporary worsening in physical functioning was observed at 6 months. Patients treated with RC (with or without NAC) experienced persistent deteriorations in body image and sexual functioning up to at least 2 years after diagnosis, although urostomy‐related outcomes improved. Patients undergoing chemoradiation showed improvements in urinary symptoms, while those receiving radiotherapy reported significant worsening of dyspnoea over time. Conclusion: In this largest population‐based study to date on HRQoL in MIBC, HRQoL largely recovered to baseline levels during the first 2 years after diagnosis. However, persistent deteriorations in physical and cognitive functioning, body image, and sexual function were observed, particularly in patients treated with RC (with or without NAC).
- Open Access
- 31 May 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (7) , 1837-1845
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Purpose: To evaluate guideline adherence and variation in the recommended use of neoadjuvant chemotherapy (NAC) and the effects of this variation on survival in patients with non-metastatic muscle-invasive bladder cancer (MIBC). Patients and methods: In this nationwide, Netherlands Cancer Registry-based study, we identified 1025 patients newly diagnosed with non-metastatic MIBC between November 2017 and November 2019 who underwent radical cystectomy. Patients with ECOG performance status 0–1 and creatinine clearance ≥ 50 mL/min/1.73 m2 were considered NAC-eligible. Interhospital variation was assessed using case-mix adjusted multilevel analysis. A Cox proportional hazards model was used to evaluate the association between hospital specific probability of using NAC and survival. All analyses were stratified by disease stage (cT2 versus cT3-4a). Results: In total, of 809 NAC-eligible patients, only 34% (n = 277) received NAC. Guideline adherence for NAC in cT2 was 26% versus 55% in cT3-4a disease. Interhospital variation was 7–57% and 31–62%, respectively. A higher hospital specific probability of NAC might be associated with a better survival, but results were not statistically significant (HRcT2 = 0.59, 95% CI 0.33–1.05 and HRcT3-4a = 0.71, 95% CI 0.25–2.04). Conclusion: Guideline adherence regarding NAC use is low and interhospital variation is large, especially for patients with cT2-disease. Although not significant, our data suggest that survival of patients diagnosed in hospitals more inclined to give NAC might be better. Further research is warranted to elucidate the underlying mechanism. As literature clearly shows the potential survival benefit of NAC in patients with cT3-4a disease, better guideline adherence might be pursued.
- 31 May 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (7) , 1837-1845
Open AccessLow adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Purpose: To evaluate guideline adherence and variation in the recommended use of neoadjuvant chemotherapy (NAC) and the effects of this variation on survival in patients with non-metastatic muscle-invasive bladder cancer (MIBC). Patients and methods: In this nationwide, Netherlands Cancer Registry-based study, we identified 1025 patients newly diagnosed with non-metastatic MIBC between November 2017 and November 2019 who underwent radical cystectomy. Patients with ECOG performance status 0–1 and creatinine clearance ≥ 50 mL/min/1.73 m2 were considered NAC-eligible. Interhospital variation was assessed using case-mix adjusted multilevel analysis. A Cox proportional hazards model was used to evaluate the association between hospital specific probability of using NAC and survival. All analyses were stratified by disease stage (cT2 versus cT3-4a). Results: In total, of 809 NAC-eligible patients, only 34% (n = 277) received NAC. Guideline adherence for NAC in cT2 was 26% versus 55% in cT3-4a disease. Interhospital variation was 7–57% and 31–62%, respectively. A higher hospital specific probability of NAC might be associated with a better survival, but results were not statistically significant (HRcT2 = 0.59, 95% CI 0.33–1.05 and HRcT3-4a = 0.71, 95% CI 0.25–2.04). Conclusion: Guideline adherence regarding NAC use is low and interhospital variation is large, especially for patients with cT2-disease. Although not significant, our data suggest that survival of patients diagnosed in hospitals more inclined to give NAC might be better. Further research is warranted to elucidate the underlying mechanism. As literature clearly shows the potential survival benefit of NAC in patients with cT3-4a disease, better guideline adherence might be pursued.
- Top Cited Papers
- 13 March 2023
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 20 (5) , 287-304
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice
Bladder cancer is among the ten most common cancers globally, causes considerable morbidity and mortality and is, therefore, a substantial burden for health-care systems. The incidence of bladder cancer is affected by demographic trends, most notably population growth and ageing, as well as exposure to risk factors, especially tobacco smoking. Consequently, the incidence has not been stable throughout the world over time, nor will it be in the near future. Further primary prevention efforts are of the utmost importance to reduce the medical and financial burden of bladder cancer on populations and health-care systems. Simultaneously, less-invasive and lower-cost approaches for the diagnosis of both primary and recurrent bladder cancers are required to address challenges posed by the increasing shortage of health-care professionals and limited financial resources worldwide. In this regard, urinary biomarkers have demonstrated promising diagnostic accuracy and efficiency. Awareness of the risk factors and symptoms of bladder cancer should also be increased in society, particularly among health-care professionals and high-risk groups. Studies investigating the associations between lifestyle factors and bladder cancer outcomes are scarce and should be a research priority. In this Review, we outline global trends in bladder cancer incidence and mortality, and discuss the main risk factors influencing bladder cancer occurrence and outcomes. We then discuss the implications, challenges and opportunities of these epidemiological trends for public health and clinical practice.
- 13 March 2023
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 20 (5) , 287-304
Top Cited PapersGlobal trends in the epidemiology of bladder cancer: challenges for public health and clinical practice
Bladder cancer is among the ten most common cancers globally, causes considerable morbidity and mortality and is, therefore, a substantial burden for health-care systems. The incidence of bladder cancer is affected by demographic trends, most notably population growth and ageing, as well as exposure to risk factors, especially tobacco smoking. Consequently, the incidence has not been stable throughout the world over time, nor will it be in the near future. Further primary prevention efforts are of the utmost importance to reduce the medical and financial burden of bladder cancer on populations and health-care systems. Simultaneously, less-invasive and lower-cost approaches for the diagnosis of both primary and recurrent bladder cancers are required to address challenges posed by the increasing shortage of health-care professionals and limited financial resources worldwide. In this regard, urinary biomarkers have demonstrated promising diagnostic accuracy and efficiency. Awareness of the risk factors and symptoms of bladder cancer should also be increased in society, particularly among health-care professionals and high-risk groups. Studies investigating the associations between lifestyle factors and bladder cancer outcomes are scarce and should be a research priority. In this Review, we outline global trends in bladder cancer incidence and mortality, and discuss the main risk factors influencing bladder cancer occurrence and outcomes. We then discuss the implications, challenges and opportunities of these epidemiological trends for public health and clinical practice.
- Open Access
- 28 February 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 183, 109584
Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study
- 28 February 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 183, 109584
Open AccessChemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: A nationwide cohort study
- Open Access
- 4 April 2022
- Published by SAGE Publications in Bladder Cancer
- Vol. 8 (2) , 139-154
The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands
BACKGROUND: The COVID-19 pandemic has disrupted regular health care with potential consequences for non-COVID diseases like cancer. To ensure continuity of oncological care, guidelines were temporarily adapted. OBJECTIVE: To evaluate the impact of the COVID-19 outbreak on bladder cancer care in the Netherlands. METHODS: The number of bladder cancer (BC) diagnoses per month during 2020-2021 was compared to 2018-2019 based on preliminary data from the Netherlands Cancer Registry (NCR). Additionally, detailed data were retrieved from the NCR for the cohort diagnosed between March 1 st -May 31 st 2020 (first COVID wave) and 2018-2019 (reference cohort). BC diagnoses, changes in age and stage at diagnosis, and time to first-line treatment were compared between both periods. Changes in treatment were evaluated using logistic regression. RESULTS: During the first COVID wave (week 9–22), the number of BC diagnoses decreased by 14%, corresponding with approximately 300 diagnoses, but increased again in the second half of 2020. The decline was most pronounced from week 13 onwards in patients≥70 years and patients with non-muscle invasive BC. Patients with muscle-invasive disease were less likely to undergo a radical cystectomy (RC) in week 17–22 (OR = 0.62, 95% CI = 0.40–0.97). Shortly after the start of the outbreak, use of neoadjuvant chemotherapy decreased from 34% to 25% but this (non-significant) effect disappeared at the end of April. During the first wave, 5% more RCs were performed compared to previous years. Time from diagnosis to RC became 6 days shorter. Overall, a 7% reduction in RCs was observed in 2020. CONCLUSIONS: The number of BC diagnoses decreased steeply by 14% during the first COVID wave but increased again to pre-COVID levels by the end of 2020 (i.e. 600 diagnoses/month). Treatment-related changes remained limited and followed the adapted guidelines. Surgical volume was not compromised during the first wave. Altogether, the impact of the first COVID-19 outbreak on bladder cancer care in the Netherlands appears to be less pronounced than was reported for other solid tumors, both in the Netherlands and abroad. However, its impact on bladder cancer stage shift and long-term outcomes, as well as later pandemic waves remain so far unexamined.
- 4 April 2022
- Published by SAGE Publications in Bladder Cancer
- Vol. 8 (2) , 139-154
Open AccessThe Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands
BACKGROUND: The COVID-19 pandemic has disrupted regular health care with potential consequences for non-COVID diseases like cancer. To ensure continuity of oncological care, guidelines were temporarily adapted. OBJECTIVE: To evaluate the impact of the COVID-19 outbreak on bladder cancer care in the Netherlands. METHODS: The number of bladder cancer (BC) diagnoses per month during 2020-2021 was compared to 2018-2019 based on preliminary data from the Netherlands Cancer Registry (NCR). Additionally, detailed data were retrieved from the NCR for the cohort diagnosed between March 1 st -May 31 st 2020 (first COVID wave) and 2018-2019 (reference cohort). BC diagnoses, changes in age and stage at diagnosis, and time to first-line treatment were compared between both periods. Changes in treatment were evaluated using logistic regression. RESULTS: During the first COVID wave (week 9–22), the number of BC diagnoses decreased by 14%, corresponding with approximately 300 diagnoses, but increased again in the second half of 2020. The decline was most pronounced from week 13 onwards in patients≥70 years and patients with non-muscle invasive BC. Patients with muscle-invasive disease were less likely to undergo a radical cystectomy (RC) in week 17–22 (OR = 0.62, 95% CI = 0.40–0.97). Shortly after the start of the outbreak, use of neoadjuvant chemotherapy decreased from 34% to 25% but this (non-significant) effect disappeared at the end of April. During the first wave, 5% more RCs were performed compared to previous years. Time from diagnosis to RC became 6 days shorter. Overall, a 7% reduction in RCs was observed in 2020. CONCLUSIONS: The number of BC diagnoses decreased steeply by 14% during the first COVID wave but increased again to pre-COVID levels by the end of 2020 (i.e. 600 diagnoses/month). Treatment-related changes remained limited and followed the adapted guidelines. Surgical volume was not compromised during the first wave. Altogether, the impact of the first COVID-19 outbreak on bladder cancer care in the Netherlands appears to be less pronounced than was reported for other solid tumors, both in the Netherlands and abroad. However, its impact on bladder cancer stage shift and long-term outcomes, as well as later pandemic waves remain so far unexamined.
- Open Access
- 8 February 2022
- Published by Wiley in BJU International
- Vol. 130 (6) , 764-775
Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
Objectives: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non‐metastatic muscle‐invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods: For this cohort study, 15 047 patients diagnosed with cT2–T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs ≥75 years). Results: One‐third of patients aged ≥75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged ≥75 years, ranging from 37% to 69% (case‐mix‐adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1–7.3) vs 16.0 months (95% CI 13.5–19.1) for treated patients. Conclusion: On average, one in five patients with non‐metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision‐making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life‐prolonging treatment.
- 8 February 2022
- Published by Wiley in BJU International
- Vol. 130 (6) , 764-775
Open AccessNon‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
Objectives: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non‐metastatic muscle‐invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods: For this cohort study, 15 047 patients diagnosed with cT2–T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs ≥75 years). Results: One‐third of patients aged ≥75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged ≥75 years, ranging from 37% to 69% (case‐mix‐adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1–7.3) vs 16.0 months (95% CI 13.5–19.1) for treated patients. Conclusion: On average, one in five patients with non‐metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision‐making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life‐prolonging treatment.
- Open Access
- 28 September 2021
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (1) , 111-118
Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients
Purpose: Little is known about the prevalence of occult lymph node metastases (LNM) in muscle-invasive bladder cancer (MIBC) patients with pathological downstaging of the primary tumor. We aimed to estimate the prevalence of occult LNM in patients without residual MIBC at radical cystectomy (RC) with or without neoadjuvant chemotherapy (NAC) or neoadjuvant radiotherapy (NAR), and to assess overall survival (OS). Methods: Patients with cT2-T4aN0M0 urothelial MIBC who underwent RC plus pelvic lymph node dissection (PLND) with curative intent between January 1995–December 2013 (retrospective Netherlands Cancer Registry (NCR) cohort) and November 2017–October 2019 (prospective NCR-BlaZIB cohort (acronym in Dutch: BlaaskankerZorg In Beeld; in English: Insight into bladder cancer care)) were identified from the nationwide NCR. The prevalence of occult LNM was calculated and OS of patients with <(y)pT2N0 vs. <(y)pT2N+ disease was estimated by the Kaplan–Meier method. Results: In total, 4657 patients from the NCR cohort and 760 patients from the NCR-BlaZIB cohort were included. Of 1374 patients downstaged to <(y)pT2, 4.3% (N = 59) had occult LNM 4.1% (N = 49) of patients with cT2-disease and 5.6% (N = 10) with cT3-4a-disease. This was 4.0% (N = 44) in patients without NAC or NAR, 4.5% (N = 10) in patients with NAC, and 13.5% (N = 5) in patients with NAR but number of patients treated with NAR and downstaged disease was small. The prevalence of <(y)pT2N+ disease was 4.2% (N = 48) in the NCR cohort and 4.6% (N = 11) in the NCR-BlaZIB cohort. For patients with <(y)pT2N+ and <(y)pT2N0, median OS was 3.5 years (95% CI 2.5–8.9) versus 12.9 years (95% CI 11.7–14.0), respectively. Conclusion: Occult LNM were found in 4.3% of patients with cT2-4aN0M0 MIBC with (near-) complete downstaging of the primary tumor following RC plus PLND. This was regardless of NAC or clinical T-stage. Patients with occult LNM showed considerable worse survival. These results can help in counseling patients for bladder-sparing treatments.
- 28 September 2021
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (1) , 111-118
Open AccessOccult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients
Purpose: Little is known about the prevalence of occult lymph node metastases (LNM) in muscle-invasive bladder cancer (MIBC) patients with pathological downstaging of the primary tumor. We aimed to estimate the prevalence of occult LNM in patients without residual MIBC at radical cystectomy (RC) with or without neoadjuvant chemotherapy (NAC) or neoadjuvant radiotherapy (NAR), and to assess overall survival (OS). Methods: Patients with cT2-T4aN0M0 urothelial MIBC who underwent RC plus pelvic lymph node dissection (PLND) with curative intent between January 1995–December 2013 (retrospective Netherlands Cancer Registry (NCR) cohort) and November 2017–October 2019 (prospective NCR-BlaZIB cohort (acronym in Dutch: BlaaskankerZorg In Beeld; in English: Insight into bladder cancer care)) were identified from the nationwide NCR. The prevalence of occult LNM was calculated and OS of patients with <(y)pT2N0 vs. <(y)pT2N+ disease was estimated by the Kaplan–Meier method. Results: In total, 4657 patients from the NCR cohort and 760 patients from the NCR-BlaZIB cohort were included. Of 1374 patients downstaged to <(y)pT2, 4.3% (N = 59) had occult LNM 4.1% (N = 49) of patients with cT2-disease and 5.6% (N = 10) with cT3-4a-disease. This was 4.0% (N = 44) in patients without NAC or NAR, 4.5% (N = 10) in patients with NAC, and 13.5% (N = 5) in patients with NAR but number of patients treated with NAR and downstaged disease was small. The prevalence of <(y)pT2N+ disease was 4.2% (N = 48) in the NCR cohort and 4.6% (N = 11) in the NCR-BlaZIB cohort. For patients with <(y)pT2N+ and <(y)pT2N0, median OS was 3.5 years (95% CI 2.5–8.9) versus 12.9 years (95% CI 11.7–14.0), respectively. Conclusion: Occult LNM were found in 4.3% of patients with cT2-4aN0M0 MIBC with (near-) complete downstaging of the primary tumor following RC plus PLND. This was regardless of NAC or clinical T-stage. Patients with occult LNM showed considerable worse survival. These results can help in counseling patients for bladder-sparing treatments.